TY - JOUR
T1 - Reliability of the Multiplex CytoBead CeliAK Immunoassay to Assess Anti-tTG IgA for Celiac Disease Screening
AU - Abdukhakimova, Diyora
AU - Dossybayeva, Kuanysh
AU - Grechka, Anna
AU - Almukhamedova, Zhaina
AU - Boltanova, Alyona
AU - Kozina, Larissa
AU - Nurgaliyeva, Kadisha
AU - Hasanova, Liliya
AU - Tanko, Matthew N.
AU - Poddighe, Dimitri
N1 - Funding Information:
This research was funded by the Nazarbayev University, Grant Number 240919FD3912.
Publisher Copyright:
© Copyright © 2021 Abdukhakimova, Dossybayeva, Grechka, Almukhamedova, Boltanova, Kozina, Nurgaliyeva, Hasanova, Tanko and Poddighe.
PY - 2021/9/21
Y1 - 2021/9/21
N2 - Background and Objective: The diagnosis of Celiac Disease (CD) is first based on the positivity for specific serological markers. The CytoBead CeliAK immunoassay simultaneously measures antibodies (IgA) directed to tissue transglutaminase (tTG), endomysium (EMA), and deamidated gliadin (DG), in addition to providing a control for total IgA levels. The aim of this study is to assess the reliability of this multiplex assay to detect anti-tTG IgA positive patients, compared with a conventional single-parameter enzyme-linked immunosorbent assay (ELISA). Methods: Serum samples from 149 pediatric patients were assessed by both CytoBead CeliAK immunoassay and ELISA, in order to evaluate their concordance for the measurement of anti-tTG IgA. Results: The measurement of anti-tTG IgA by CytoBead CeliAK immunoassay basically showed a complete concordance rate with the conventional and single-parameter ELISA, according to the respective cutoff values (3 U/ml and 10 U/ml). Conclusions: Our comparative analysis demonstrates a substantial equivalency between multiplex CytoBead CeliAK assay and the single-parameter conventional ELISA to assess anti-tTG IgA antibody in the context of the screening for CD in children. Importantly, CytoBead CeliAK assay could present some preanalytic, analytic, and economic advantages.
AB - Background and Objective: The diagnosis of Celiac Disease (CD) is first based on the positivity for specific serological markers. The CytoBead CeliAK immunoassay simultaneously measures antibodies (IgA) directed to tissue transglutaminase (tTG), endomysium (EMA), and deamidated gliadin (DG), in addition to providing a control for total IgA levels. The aim of this study is to assess the reliability of this multiplex assay to detect anti-tTG IgA positive patients, compared with a conventional single-parameter enzyme-linked immunosorbent assay (ELISA). Methods: Serum samples from 149 pediatric patients were assessed by both CytoBead CeliAK immunoassay and ELISA, in order to evaluate their concordance for the measurement of anti-tTG IgA. Results: The measurement of anti-tTG IgA by CytoBead CeliAK immunoassay basically showed a complete concordance rate with the conventional and single-parameter ELISA, according to the respective cutoff values (3 U/ml and 10 U/ml). Conclusions: Our comparative analysis demonstrates a substantial equivalency between multiplex CytoBead CeliAK assay and the single-parameter conventional ELISA to assess anti-tTG IgA antibody in the context of the screening for CD in children. Importantly, CytoBead CeliAK assay could present some preanalytic, analytic, and economic advantages.
KW - anti-tissue transglutaminase antibody
KW - celiac disease
KW - children
KW - ELISA
KW - immunoglobulin A
KW - multiplex assay
KW - screening
UR - https://www.scopus.com/pages/publications/85116469904
UR - https://www.scopus.com/pages/publications/85116469904#tab=citedBy
U2 - 10.3389/fmed.2021.731067
DO - 10.3389/fmed.2021.731067
M3 - Article
AN - SCOPUS:85116469904
SN - 2296-858X
VL - 8
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 731067
ER -